Effect of intravenous clarithromycin in patients with sepsis, respiratory and multiple organ dysfunction syndrome: a randomized clinical trial

BACKGROUND: Clarithromycin may act as immune-regulating treatment in sepsis and acute respiratory dysfunction syndrome. However, clinical evidence remains inconclusive. We aimed to evaluate whether clarithromycin improves 28-day mortality among patients with sepsis, respiratory and multiple organ dy...

Descripción completa

Detalles Bibliográficos
Autores principales: Karakike, Eleni, Scicluna, Brendon P., Roumpoutsou, Maria, Mitrou, Ioannis, Karampela, Niki, Karageorgos, Athanasios, Psaroulis, Konstantinos, Massa, Eleni, Pitsoulis, Achillefs, Chaloulis, Panagiotis, Pappa, Evanthia, Schrijver, Irene T., Frantzeskaki, Frantzeska, Lada, Malvina, Dauby, Nicolas, De Bels, David, Floros, Ioannis, Anisoglou, Souzana, Antoniadou, Eleni, Patrani, Maria, Vlachogianni, Glykeria, Mouloudi, Eleni, Antoniadou, Anastasia, Grimaldi, David, Roger, Thierry, Wiersinga, W. Joost, Tsangaris, Iraklis, Giamarellos-Bourboulis, Evangelos J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206755/
https://www.ncbi.nlm.nih.gov/pubmed/35717241
http://dx.doi.org/10.1186/s13054-022-04055-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206755/
https://www.ncbi.nlm.nih.gov/pubmed/35717241
http://dx.doi.org/10.1186/s13054-022-04055-4

Ejemplares similares